Yahoo Finance·2025-12-31 14:15Group 1 - The article highlights the potential for above-average market returns by identifying underperforming stocks that may rebound, particularly in the context of a strong overall market performance [1] - Viking Therapeutics and Zoetis are identified as two healthcare stocks that have underperformed in 2025 but may see significant improvements in 2026 [2] - Viking Therapeutics is a clinical-stage biotech company with promising developments in weight management, specifically its investigational GLP-1 anti-obesity medicine VK2735, which is currently in phase 3 studies [4][5] Group 2 - Viking Therapeutics has faced challenges due to profit-taking by investors and high patient dropout rates in mid-stage trials, but the efficacy of VK2735 remains strong, suggesting potential for recovery [6][7] - The company is developing an oral formulation of VK2735, which could enhance its market position in the growing weight loss drug sector [5][6] - Positive clinical and regulatory progress for Viking Therapeutics could lead to a rebound in its stock price as early as next year, making it a stock worth considering [7]